<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867750</url>
  </required_header>
  <id_info>
    <org_study_id>SX-PHCC-001</org_study_id>
    <secondary_id>STX0306</secondary_id>
    <nct_id>NCT00867750</nct_id>
  </id_info>
  <brief_title>SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <acronym>SIRTACE</acronym>
  <official_title>Radioembolisation (RE) With SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC). A Comparative, Prospective, Randomised, Open, Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirtex Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sirtex Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to patients with primary HCC who cannot be treated by potentially curative
      treatment modalities, such as surgical resection, liver transplantation or percutaneous
      ablation.

      Patients that satisfy the study eligibility criteria will be randomised in a 1: 1 ratio to
      receive either Radioembolisation with SIR-Spheres Microspheres or the standardised
      Transarterial Chemoembolisation procedure.

      Study Objectives

      This study will evaluate and compare quality of life as well as safety and efficacy of RE or
      TACE in patients with unresectable HCC. Patients will be followed for a minimum of 12 months
      or until death wherever possible in the evaluation of the primary and secondary objectives of
      this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life (HRQL)</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS); calculated from the date of first treatment</measure>
    <time_frame>From the date of first treatment until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphological tumour response; assessed using RESIST criteria</measure>
    <time_frame>From the date of first treatment until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional tumour response; assessed via tumour marker reduction</measure>
    <time_frame>From the date of first treatment until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 6 and 12 months</measure>
    <time_frame>6 and 12 months from the date of first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of first treatment until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of portal vein invasion</measure>
    <time_frame>From the date of first treatment until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of extra-hepatic disease</measure>
    <time_frame>From the date of first treatment until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmaco-economic assessment</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>RE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Radioembolisation with yttrium-90 labelled SIR-Spheres microspheres</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transarterial Chemoembolisation with embolising agent Embospheres and chemotherapeutic agent epirubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radioembolisation (SIR-Spheres® microspheres)</intervention_name>
    <description>Yttrium-90 SIR-Spheres microspheres</description>
    <arm_group_label>RE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transarterial Chemoembolisation</intervention_name>
    <description>TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.</description>
    <arm_group_label>TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, aged ≥ 18 years

          -  Unequivocal diagnosis of primary HCC (confirmed by biopsy/histology or EASL criteria)

          -  Tumour characteristics as follows:

               -  Not more than 5 lesions

               -  If single, maximal diameter ≤ 10 cm

               -  If multiple, sum of maximal diameters ≤ 15 cm

               -  Lesions satellite to primary tumour of less than 1 cm in maximal diameter are not
                  included

               -  At least one quantifiable lesion on hepatic MRI

          -  Preserved liver function, corresponding to Child-Pugh class ≤ B-7

          -  ECOG performance status ≤ 2

          -  Life expectancy ≥ 12 weeks

          -  Female patients of childbearing potential must have a negative pregnancy test prior to
             inclusion in the trial and male and female patients must agree to use an effective
             contraceptive method for the duration of the trial.

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Patients expected to undergo surgery (resection or transplantation) within the 24-week
             period after randomisation.

          -  Ascites, which is detectable on physical examination or clinically symptomatic (but
             patients having ascites discovered by imaging only should not be excluded).

          -  Serum transaminases &gt; 5 x ULN

          -  Lung shunt &gt; 20%

          -  Extrahepatic disease

          -  Moderate to severe portal hypertension, as evidenced by any of the following criteria
             (occurring in spite of using common criteria for prophylactic treatment and therapy):

               -  History of variceal haemorrhage in past 2 years

               -  History of hepatic encephalopathy

               -  Platelets &lt; 50.000 /ml

               -  WBC &lt; 3.000 / ml

               -  Previous TIPSS procedure

          -  Portal vein occlusion or hepatofugal flow.

          -  Impaired liver function

               -  Total serum bilirubin &gt; 2.0 mg / dL

               -  Serum albumin &lt; 3.0 g /dl

               -  creatinine &gt; 2 mg / dL

          -  Chemotherapy or other experimental therapy within preceding 4 weeks

          -  Previous TAE / TACE

          -  Previous radiation therapy to liver or lungs

          -  Contraindications for angiography (severe peripheral vascular disease or uncorrectable
             bleeding diathesis)

          -  Anatomical variants apparent on 99mTc-MAA scan precluding safe administration of RE

          -  Any decompensated concomitant disease

          -  Female patients who are pregnant, breast-feeding, or pre-menopausal and not practising
             efficient contraceptive method (hormonal contraceptive, intra-uterine device)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Bruno Sangro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Frank Kolligs, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäts-Klinikum München-Grosshadern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Klinikum München-Grosshadern, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>München</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>E-31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>RE</keyword>
  <keyword>Yttrium-90</keyword>
  <keyword>SIR-Spheres microspheres</keyword>
  <keyword>TACE</keyword>
  <keyword>Radioembolisation</keyword>
  <keyword>Transarterial Chemoembolisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

